Paul Hudson, Sanofi CEO (Photographer: Cyril Marcilhacy/Bloomberg via Getty Images)

Sanofi, Re­gen­eron’s Dupix­ent scores an­oth­er in­di­ca­tion with first-ever ap­proval for nodu­lar skin dis­or­der

Sanofi chief ex­ec­u­tive Paul Hud­son told in­vestors ear­li­er this year that the Big Phar­ma was go­ing to em­pha­size its sales king­pin Dupix­ent mov­ing for­ward.

He wasn’t jok­ing — the megablock­buster drug and sales king, record­ing just shy of $2 bil­lion in sales this past quar­ter, has now of­fi­cial­ly se­cured its fifth in­di­ca­tion from the FDA.

Sanofi and Re­gen­eron, who joint­ly work on Dupix­ent de­vel­op­ment and com­mer­cial­iza­tion, an­nounced the new de­vel­op­ment on Thurs­day, say­ing that the FDA gave the all-clear to Dupix­ent to treat pa­tients with pruri­go nodu­laris, a rare au­toim­mune dis­or­der char­ac­ter­ized by a per­sis­tent, se­vere itch — and al­so vi­su­al­ized by hard, ex­treme­ly itchy bumps known as nod­ules that form on the skin. The FDA not­ed in its an­nounce­ment that it is the agency’s first ap­proval for the dis­ease.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.